Table 1 Information of cohorts used in this work.

From: Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

Cohort name

Tumour type

Cohort size

Target checkpoint

Reference

SMC

Lung cancer

122

PD-1/PD-L1

This work

Hellmann

Lung cancer

75

PD-1 & CTLA-4

Ref. 25

Rizvi

Lung cancer

34

PD-1

Ref. 24

Van Allen

Melanoma

110

CTLA-4

Ref. 21

Snyder

Melanoma

64

CTLA-4

Ref. 22

Roh

Melanoma

56

PD-1 & CTLA-4

Ref. 10

Riaz

Melanoma

68

PD-1

Ref. 12